In order to develop the most effective immunotherapies possible, Acepodia equips its ACC technology to both of its proprietary gamma delta2 (γδ2) T cells and off-the-shelf NK (oNK) cells which are allogeneic, and specially selected for enhanced tumor engagement. ACC allows for any antibody, new or existing, to be conjugated to the stimulatory surface receptors of these immune cells to yield the additive effect of superior tumor targeting to our already potent and off-the-shelf biologic drug payloads.